32results about How to "Minimizing side-effects" patented technology

The present invention relates to compositions and methods for treating diseases and disorders including cancer and various other angiogenic-dependent diseases, vascular malfunctions, arteriovenous malformations (AVM), hemorrhagic processes and treatment of pain, in particular tumor-related pain by drug delivery and / or therapeutic embolization using microspheres. More particularly the invention relates to microspheres containing non-ionic contrast agents, to compositions comprising these microspheres, as well as methods for preparing and using such compositions for embolization therapy. The invention further relates to compositions and methods using detectable microspheres for targeted drug delivery, irrespective of whether embolization is also needed.

This invention relates to a pharmaceutical composition for oral administration comprising a carrier and, as active ingredient, an opioid (μ receptor) agonist, such as fentanyl, or a salt thereof, characterized in that the composition is in the form of a fast-dispersing dosage form designed to release the active ingredient rapidly in the oral cavity. A process for preparing such a composition and the use of such a composition as an analgesic, for the treatment of chronic pain and / or breakthrough pain, as an anesthetic premedication, for the induction of anesthesia, as a sedative and / or for the treatment of anxiety are also provided.

The present invention is directed to sublingual formulations containing fentanyl, a pharmaceutically acceptable salt thereof, or derivative thereof, suitable for administration to a patient, and methods for treatment with the formulations.

Transactional programming promises to substantially simplify the development and maintenance of correct, scalable, and efficient concurrent programs. Designs for supporting transactional programming using transactional memory implemented in hardware, software, and a mixture of the two have emerged recently. Unfortunately, conventional debugging programs are often inadequate when employed in relation to code that employs transactional memory and new or modified techniques are needed. Implementations of delayed breakpoints are described that provide programmers with the benefits of breakpoints in transactional code, while minimizing the side-effects of breakpoints placed inside atomic block.

Transactional programming promises to substantially simplify the development and maintenance of correct, scalable, and efficient concurrent programs. Designs for supporting transactional programming using transactional memory implemented in hardware, software, and a mixture of the two have emerged recently. Unfortunately, conventional debugging programs are often inadequate when employed in relation to code that employs transactional memory and new or modified techniques are needed. Implementations of delayed breakpoints are described that provide programmers with the benefits of breakpoints in transactional code, while minimizing the side-effects of breakpoints placed inside atomic block.

Object of the present invention is to provide various anti-podoplanin antibodies useful as a drug or reagent. The present invention provides an anti-podoplanin antibody or antigen-binding fragment thereof, each having an epitope in any of the following regions in the amino acid sequence of podoplanin represented by SEQ ID NO: 1: (i) from position 56 to position 80, (ii) from position 81 to position 103, (iii) from position 81 to position 88, and (iv) from position 25 to position 57.

The present invention is directed to sublingual formulations containing fentanyl, a pharmaceutically acceptable salt thereof, or derivative thereof, suitable for administration to a patient, and methods for treatment with the formulations.

The present invention describes chemically modified avidins that have higher permanence in treated tissues compared to wild type avidin. Avidin oxidation is performed by periodate incubation in the presence of the low affinity ligand HABA which, occupying the biotin binding sites, prevents protein denaturation during the oxidation step. Periodate oxidation generates CHO groups from avidin mannose ring opening that, once injected, react with tissue NH2 residues to form stable Schiff's bases. The anchored avidins maintain the ability to bind biotinylated agents endowed of therapeutic activity, like radiolabeled biotins, stem cells and somatic cells, useful for brachytherapies like Intraoperative Avidination Radionuclide Therapy (IART®) or degenerative or genetic diseases.

The present invention is theobromine as an active agent to be delivered via the inhaled route, for the treatment of cough.

A controlled-release pharmaceutical composition including first and second groups of microparticles, each of the microparticles including a core including tamsulosin or pharmaceutically acceptable salts thereof, a controlled-release polymer coating layer formed on the core, and an enteric polymer outer layer formed on the controlled-release polymer coating layer, wherein the average thickness of the controlled-release polymer coating layer is different in each of the first and second groups of microparticles, and an oral formulation including the same, are provided. This pharmaceutical composition can easily control the extent of release of an active ingredient depending on changes in pH in the intestinal tract and the release pattern of the active ingredient in the small intestine, thus preventing the active ingredient from being rapidly transferred into the blood to thereby minimize side-effects, and maintaining the effective blood concentration of the active ingredient for a predetermined period of time. Furthermore, this composition can shield the bitter taste of the active ingredient even when exposed to the inside of the mouth, thus increasing the therapeutic effects for patients upon oral administration.

A non-opioid analgesic is used for the treatment of intermittent or episodic pain experienced by a patient undergoing chronic pain treatment with an opioid analgesic.

This invention describes a genetic system for targeting the EVI1 gene in mammalian cells. The EVI1 gene is an oncogenic transcription factor that, when expressed, accelerates cell division and inhibits death of cells. Nucleotide sequences that block the expression of EVI1 and drug delivery systems for them are described. These nucleotide sequences cause a block in cell growth and division and trigger death of mammalian cells, including lung and ovarian cancer cells.

The invention provides for a system for visualizing a medical treatment of a human or animal body part. The system has means for thermal treatment of the body part, means for determining the temperature distribution on the body part, and means for identifying the location of a particular temperature determined on the body part. Further, a method for visualizing the temperature characteristics of a human or animal body part is provided. The method has the steps of comparing a first temperature distribution data set of the surface of the body part with a second temperature distribution data set of the surface of the body part, wherein the first temperature distribution data set is determined before and the second temperature distribution data set is determined after a thermal treatment of the body part, and visualizing the temperature distribution data sets of the body part. Furthermore, a computer program product is provided. The computer program product has one or more computer readable media having computer executable instructions for actuating and controlling the steps of the method discussed hereinbefore.

The present invention relates to a bellows framework having a concave-convex structure on at least one of outer and inner sides using three-dimensional printing technology and a method of producing thereof, and an artificial tracheal replacement comprising an epithelium part formed on the inner side of the bellows framework and an annular cartilage part formed along the circumference of concave-convex grooves on the outer side and a method of producing thereof.

A magnetic resonance device has a patient bed able to be automatically moved by means of a drive apparatus into a patient chamber, as well as a magnet arrangement for creating a magnetic field in the interior of the patient chamber. The drive apparatus is operated so as to move the patient bed at a speed determined as a function of the distribution of the magnetic field in the direction of movement of the patient bed.

The present invention describes chemically modified avidins that have higher permanence in treated tissues compared to wild type avidin. Avidin oxidation is performed by periodate incubation in the presence of the low affinity ligand HABA which, occupying the biotin binding sites, prevents protein denaturation during the oxidation step. Periodate oxidation generates CHO groups from avidin mannose ring opening that, once injected, react with tissue NH2 residues to form stable Schiff's bases. The anchored avidins maintain the ability to bind biotinylated agents endowed of therapeutic activity, like radiolabeled biotins, stem cells and somatic cells, useful for brachytherapies like Intraoperative Avidination Radionuclide Therapy (IART®) or degenerative or genetic diseases.

Object of the present invention is to provide various anti-podoplanin antibodies useful as a drug or reagent. The present invention provides an anti-podoplanin antibody or antigen-binding fragment thereof, each having an epitope in any of the following regions in the amino acid sequence of podoplanin represented by SEQ ID NO: 1: (i) from position 56 to position 80, (ii) from position 81 to position 103, (iii) from position 81 to position 88, and (iv) from position 25 to position 57.

A controlled-release pharmaceutical composition including first and second groups of microparticles, each of the microparticles including a core including tamsulosin or pharmaceutically acceptable salts thereof, a controlled-release polymer coating layer formed on the core, and an enteric polymer outer layer formed on the controlled-release polymer coating layer, wherein the average thickness of the controlled-release polymer coating layer is different in each of the first and second groups of microparticles, and an oral formulation including the same, are provided. This pharmaceutical composition can easily control the extent of release of an active ingredient depending on changes in pH in the intestinal tract and the release pattern of the active ingredient in the small intestine, thus preventing the active ingredient from being rapidly transferred into the blood to thereby minimize side-effects, and maintaining the effective blood concentration of the active ingredient for a predetermined period of time. Furthermore, this composition can shield the bitter taste of the active ingredient even when exposed to the inside of the mouth, thus increasing the therapeutic effects for patients upon oral administration.

The present invention relates to the use of bifunctional compositions in methods of treating or preventing cancer. The compositions comprise a DNA ligand and a protein ligand for the treatment or prevention of cancer, wherein the DNA ligand interferes with DNA metabolism and the protein ligand interferes with signaling pathways. In particular, the present invention relates to the use of pyronaridine in methods of treating of preventing cancer. The invention also relates to compositions, compounds and medicaments comprising a DNA ligand and a protein ligand, for example, compositions, compounds and medicaments comprising pyronaridine.

The present invention provides a method for rapidly and reliably delivering dantrolene, or derivatives thereof, alone or in combination with other compounds, to the systemic circulation by administration via the nasal route to produce rapid onset of beneficial effects in the treatment or prevention of malignant hyperthermia (MH), spasticity, and Ecstasy intoxication. The present invention further provides intranasal pharmaceutical compositions comprising dantrolene sodium or any pharmaceutically acceptable salts thereof in a variety of pharmaceutical dosage forms, with and without other compounds.

This invention relates to a gem-dinitro ester energetic material represented by Chemical Formula 1 below, which is synthesized using esterification, and to a preparation method thereof:wherein R is a C5˜C15 substituted or unsubstituted linear or branched alkyl group.

A magnetic resonance device has a patient bed able to be automatically moved by means of a drive apparatus into a patient chamber, as well as a magnet arrangement for creating a magnetic field in the interior of the patient chamber. The drive apparatus is operated so as to move the patient bed at a speed determined as a function of the distribution of the magnetic field in the direction of movement of the patient bed.

This invention relates to a gem-dinitro ester energetic material represented by Chemical Formula 1 below, which is synthesized using esterification, and to a preparation method thereof:wherein R is a C5˜C15 substituted or unsubstituted linear or branched alkyl group.

The invention relates to a method for contraception comprising the administration of trimegestone to a woman of child-bearing age on at least 21 successive days, beginning on day 1 of the menstrual cycle, wherein on at least one of the at least 21 successive days the daily dose of trimegestone is more than 500 μg.

This invention describes a genetic system for targeting the EVI1 gene in mammalian cells. The EVI1 gene is an oncogenic transcription factor that, when expressed, accelerates cell division and inhibits death of cells. Nucleotide sequences that block the expression of EVI1 and drug delivery systems for them are described. These nucleotide sequences cause a block in cell growth and division and trigger death of mammalian cells, including lung and ovarian cancer cells.

The present intervention related to materials and methods for the synthesis of lipophilic inositol glycan compounds, and salts, solvates and physiological functional derivatives thereof, and their use for the treatment of cancer and glucose-metabolism disorders, such as, for example, diabetes, obesity and metabolic syndrome.

A system for visualizing a medical treatment of a human or animal body part. The system has means for thermal treatment of the body part, means for determining the temperature distribution on the body part, and means for identifying the location of a particular temperature determined on the body part. Further, a method for visualizing the temperature characteristics of a human or animal body part is provided. The method includes the steps of comparing a first temperature distribution data set of the surface of the body part with a second temperature distribution data set of the surface of the body part, wherein the first temperature distribution data set is determined before and the second temperature distribution data set is determined after a thermal treatment of the body part, and visualizing the temperature distribution data sets of the body part.

The present invention is directed to sublingual formulations containing fentanyl, a pharmaceutically acceptable sale thereof, or derivative thereof, suitable for administration to a patient, and methods for treatment with the formulations.

The present invention relates to a low-temperature treatment device capable of preventing nerve damage. The low-temperature treatment device according to one embodiment of the present invention can comprise: a cooling pocket which is inserted and positioned in a rectum and which has a predetermined shape during expansion; and a circulation tube which has a passage through which fluid flows in and out and which is inserted into the cooling pocket so as to circulate the fluid in an inner space of the cooling pocket.